This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

CD4 T helper cells are a type of white blood cell called a lymphocyte that serves an important role in your immune system. These cells help defend the body against infection by directing other "killer ...

B-cell depletion strategies: Reduce IgA1-producing B-cell populations Second Hit (Anti-Glycan Antibody Formation) Selective immunomodulators : Target autoantibody-producing B-cell clones ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

Boehringer Ingelheim Pharma GmbH & Co KG and Cue Biopharma Inc. have signed a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501, a ...

a differentiated B cell depletion therapy for autoimmune diseases. Boston, USA-based Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to ...

The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and ...

The collaboration is set to focus on research and development of B cell depletion molecules, a therapeutic approach for autoimmune conditions. According to InvestingPro data, the company maintains ...